Moleculin Biotech, Inc. announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor and certain of the Company’s executive officers and directors to purchase 7,044,836 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
